Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 2,130 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 2,130 shares of Castle Biosciences stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $19.52, for a total value of $41,577.60. Following the sale, the insider now directly owns 78,335 shares of the company’s stock, valued at approximately $1,529,099.20. The trade was a 2.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Castle Biosciences Price Performance

Castle Biosciences stock opened at $19.63 on Thursday. The stock’s fifty day moving average price is $26.17 and its two-hundred day moving average price is $28.77. Castle Biosciences, Inc. has a one year low of $16.97 and a one year high of $35.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64. The firm has a market cap of $549.78 million, a PE ratio of 98.15 and a beta of 0.98.

Hedge Funds Weigh In On Castle Biosciences

A number of hedge funds have recently added to or reduced their stakes in the stock. Algert Global LLC increased its stake in Castle Biosciences by 0.4% during the 3rd quarter. Algert Global LLC now owns 134,321 shares of the company’s stock worth $3,831,000 after acquiring an additional 599 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of Castle Biosciences by 11.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company’s stock valued at $158,000 after purchasing an additional 604 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Castle Biosciences by 4.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,786 shares of the company’s stock valued at $394,000 after purchasing an additional 608 shares during the last quarter. Invesco Ltd. increased its stake in shares of Castle Biosciences by 2.3% in the 4th quarter. Invesco Ltd. now owns 27,534 shares of the company’s stock valued at $734,000 after purchasing an additional 616 shares during the last quarter. Finally, Assetmark Inc. increased its stake in shares of Castle Biosciences by 16.8% in the 3rd quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock valued at $149,000 after purchasing an additional 748 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on CSTL shares. Stephens reissued an “overweight” rating and set a $41.00 price target on shares of Castle Biosciences in a report on Thursday, January 2nd. Robert W. Baird lifted their price target on Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $40.00.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.